文献速递瓣膜外科

微创瓣膜手术治疗感染性心内膜炎的对比研究

Minimally Invasive Valve Surgery for Patients With Infective Endocarditis: A Comparative Study.
PubMed 文献 · Ann Thorac Surg · 2025-02-11

该研究基于STS成人心脏外科数据库,回顾了2016年7月至2024年3月因心内膜炎行瓣膜手术的741例患者,比较微创入路与传统胸骨切开。微创组二尖瓣修复率更高,但三尖瓣修复率更低,主动脉瓣无差异;风险校正后,微创入路与STS主要并发症或死亡无独立关联。

要点

  • 微创瓣膜手术治疗心内膜炎安全有效,风险校正结局与开胸手术相似。
  • 微创入路二尖瓣修复率更高(76.3% vs 48%),三尖瓣修复率更低。
  • 风险校正后,年龄、肺病、术前肌酐和瓣膜修复与主要并发症或死亡独立相关,微创入路无关联。

核心结论

  • 微创瓣膜手术治疗感染性心内膜炎安全有效,修复率和风险校正结局与开胸手术相似。

研究设计与样本

  • 基于STS成人心脏外科数据库的回顾性队列研究,纳入2016年7月至2024年3月因心内膜炎行瓣膜手术的741例患者。
  • 按传统胸骨切开与微创入路(包括半胸骨切开、右胸切开和机器人辅助)分层,采用逻辑回归进行风险校正。

主要发现

  • 微创组二尖瓣修复率76.3% vs 开胸组48%(P < .0001),三尖瓣修复率22.5% vs 44.1%(P < .0001),主动脉瓣修复率无差异(8.3% vs 7.4%,P = .372)。
  • 风险校正前,微创组阻断时间更长(99分钟 vs 86分钟,P = 0.019),但STS主要并发症或死亡率更低(15.4% vs 27.8%,P = 0.019)。
  • 风险校正后,年龄(OR 1.1,P = 0.008)、肺病(OR 2.2,P = 0.010)、术前肌酐(OR 1.3,P = 0.016)和瓣膜修复(OR 0.17,P = 0.002)与STS主要并发症或死亡独立相关,微创入路无独立关联(OR 1.2,P = 0.807)。

关键数值与推荐

  • 微创入路包括半胸骨切开、右胸切开和机器人辅助瓣膜手术。
  • 主要结局为STS主要并发症或死亡,采用当前STS风险模型中的协变量进行风险校正。

临床怎么用

  • 对于感染性心内膜炎患者,微创瓣膜手术可作为传统开胸手术的可行替代,尤其适用于二尖瓣修复。
  • 需注意微创入路可能降低三尖瓣修复率,选择术式时应综合考虑瓣膜位置和修复可能性。

局限性

  • 回顾性单中心数据库研究,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with endocarditis frequently require valve surgical procedure, and despite the recent growth of minimally invasive cardiac surgery (MICS) for complex valve operations, consensus recommendations still suggest conventional sternotomy. METHODS: The institutional Adult Cardiac Surgery Database of The Society of Thoracic Surgeons (STS) evaluated all patients undergoing valve surgical procedure for endocarditis from July 2016 to March 2024. Patients were stratified by conventional sternotomy vs an MICS approach, including hemisternotomy, right thoracotomy, and robotic-assisted mitral, tricuspid, or aortic valve surgical procedure. Logistic regression assessed the risk-adjusted association with the primary outcomes of STS major morbidity or mortality and the MICS approach by accounting for all covariates in current STS risk models. RESULTS: Of 741 patients undergoing valve surgical procedure for endocarditis, the median age was 37 years, 582 (78.5%) had a substance use disorder, 210 (28.3%) underwent redo sternotomies, and 166 (22.4%) had redo valve operations. MICS was associated with a higher repair rate for mitral valves (76.3% vs 48%; P < .0001) but a lower rate for tricuspid valve (22.5% vs 44.1%; P < .0001), with no difference for aortic valves (8.3% vs 7.4%; P = .372). Before risk adjustment, MICS was associated with longer cross-clamp times (99 minutes vs 86 minutes; P = 0.019) but a lower incidence of STS major morbidity or mortality (15.4% vs 27.8%; P = 0.019). After robust risk adjustment, age (odds ratio [OR], 1.1; P = 0.008), lung disease (OR, 2.2; P = 0.010), preoperative creatinine (OR, 1.3; P = 0.016), and valve repair vs replacement (OR, 0.17; P = 0.002), but not MICS (OR, 1.2; P = 0.807), were independently associated with STS major morbidity and mortality. CONCLUSIONS: MICS valve surgical procedure for endocarditis appears both safe and effective, with repair rates and risk-adjusted outcomes similar to those of open surgical procedure.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Raikar C, Wolfe S, Lagazzi LF, et al. Minimally Invasive Valve Surgery for Patients With Infective Endocarditis: A Comparative Study. Ann Thorac Surg. 2025. PMID: 39947309. doi:10.1016/j.athoracsur.2025.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。